ULTRAGENYX PHARMACEUTICAL INC. - COMMON STOCK

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

21 أغسطس 2024 16:30:00 بحسب Nasdaq GlobeNewswire

NetDania - New 12 months High: ULTRAGENYX PHARMACEUTICAL INC. - COMMON STOCK

21 أغسطس 2024 10:00:12 بحسب NetDania Notify

Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate Update

01 أغسطس 2024 16:05:39 بحسب Nasdaq GlobeNewswire

Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update

25 يوليو 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium

24 يوليو 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

19 يوليو 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome Program

17 يوليو 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

20 يونيو 2024 16:30:00 بحسب Nasdaq GlobeNewswire

Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

13 يونيو 2024 20:49:09 بحسب Nasdaq GlobeNewswire

Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

12 يونيو 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)

12 يونيو 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)

11 يونيو 2024 17:47:59 بحسب Nasdaq GlobeNewswire

Ultragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare Conference

04 يونيو 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

30 مايو 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

17 مايو 2024 16:30:00 بحسب Nasdaq GlobeNewswire

Ultragenyx to Participate at Bank of America’s 2024 Healthcare Conference

07 مايو 2024 16:30:00 بحسب Nasdaq GlobeNewswire

Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update

02 مايو 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease

30 أبريل 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)

30 أبريل 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update

25 أبريل 2024 16:30:00 بحسب Nasdaq GlobeNewswire